Guidewire Software, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Guidewire Software, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jul 31, 2019 | $719.51M | Oct 1, 2019 |
| FY2018 | Jul 31, 2018 | $240.26M | Jun 3, 2019 |
| FY2018 | Apr 30, 2018 | $142.15M | Jun 3, 2019 |
| FY2018 | Jan 31, 2018 | $160.23M | Jun 3, 2019 |
| FY2018 | Oct 31, 2017 | $110.21M | Jun 3, 2019 |
| FY2018 | Jul 31, 2017 | $176.35M | Jun 3, 2019 |
| FY2018 | Jul 31, 2016 | $424.45M | Jun 3, 2019 |
| FY2017 | Jul 31, 2015 | $380.54M | Sep 20, 2017 |
| FY2016 | Jul 31, 2014 | $350.25M | Sep 15, 2016 |
| FY2015 | Jul 31, 2013 | $300.65M | Sep 17, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.20B | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $980.50M | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | $905.34M | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | $812.61M | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | $743.27M | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | $742.31M | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | $719.51M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $652.85M | Sep 28, 2020 |
| FY2019 | Jul 31, 2017 | $509.53M | Oct 1, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $752.05M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $583.36M | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | $458.21M | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | $377.18M | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | $389.56M | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | $404.29M | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | $395.16M | Sep 24, 2021 |
| FY2018 | Jul 31, 2018 | $149.78M | Jun 3, 2019 |
| FY2018 | Apr 30, 2018 | $66.47M | Jun 3, 2019 |
| FY2018 | Jan 31, 2018 | $92.71M | Jun 3, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $41.07M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | ($52.57M) | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | ($149.49M) | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | ($199.45M) | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | ($105.58M) | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | ($23.89M) | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | $1.47M | Sep 24, 2021 |
| FY2018 | Jul 31, 2018 | $48.10M | Jun 3, 2019 |
| FY2018 | Apr 30, 2018 | ($28.87M) | Jun 3, 2019 |
| FY2018 | Jan 31, 2018 | ($3.97M) | Jun 3, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $296.16M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $269.38M | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | $249.75M | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | $229.23M | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | $201.47M | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | $200.58M | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | $188.54M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $171.66M | Sep 28, 2020 |
| FY2019 | Jul 31, 2017 | $130.32M | Oct 1, 2019 |
| FY2018 | Jul 31, 2016 | $112.50M | Jun 3, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $300.87M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $195.75M | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | $38.40M | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | ($37.94M) | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | $111.59M | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | $113.07M | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | $116.13M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $140.46M | Sep 28, 2020 |
| FY2019 | Jul 31, 2017 | $138.76M | Oct 1, 2019 |
| FY2018 | Jul 31, 2016 | $99.90M | Jun 3, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $5.74M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $6.36M | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | $5.82M | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | $9.51M | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | $19.01M | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | $21.38M | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | $44.92M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $9.40M | Sep 28, 2020 |
| FY2019 | Jul 31, 2017 | $5.89M | Oct 1, 2019 |
| FY2018 | Jul 31, 2016 | $7.11M | Jun 3, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.72B | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $2.23B | Sep 11, 2025 |
| FY2024 | Jul 31, 2023 | $2.03B | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | $2.27B | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | $2.32B | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | $2.36B | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $2.17B | Sep 28, 2020 |
| FY2019 | Jul 31, 2018 | $1.98B | Oct 1, 2019 |
| FY2018 | Jul 31, 2017 | $1.08B | Jun 3, 2019 |
| FY2017 | Jul 31, 2016 | $916.18M | Sep 20, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.26B | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $883.56M | Sep 11, 2025 |
| FY2024 | Jul 31, 2023 | $828.42M | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | $815.24M | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | $776.95M | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | $708.08M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $592.76M | Sep 28, 2020 |
| FY2019 | Jul 31, 2018 | $567.82M | Oct 1, 2019 |
| FY2018 | Jul 31, 2017 | $190.37M | Jun 3, 2019 |
| FY2017 | Jul 31, 2016 | $132.24M | Sep 20, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.46B | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $1.34B | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | $1.20B | Sep 11, 2025 |
| FY2025 | Jul 31, 2022 | $1.45B | Sep 11, 2025 |
| FY2024 | Jul 31, 2021 | $1.54B | Sep 16, 2024 |
| FY2023 | Jul 31, 2020 | $1.66B | Sep 18, 2023 |
| FY2022 | Jul 31, 2019 | $1.57B | Sep 26, 2022 |
| FY2021 | Jul 31, 2018 | $1.41B | Sep 24, 2021 |
| FY2020 | Jul 31, 2017 | $888.53M | Sep 28, 2020 |
| FY2019 | Jul 31, 2016 | $783.94M | Oct 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $393.98M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $372.21M | Sep 11, 2025 |
| FY2024 | Jul 31, 2023 | $372.21M | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | $372.19M | Sep 18, 2023 |
| FY2023 | Aug 18, 2021 | $31.30M | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | $340.88M | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | $340.88M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $340.88M | Sep 28, 2020 |
| FY2020 | Jul 31, 2018 | $340.90M | Sep 28, 2020 |
| FY2019 | Jul 31, 2017 | $141.85M | Oct 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($554.25M) | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | ($624.05M) | Sep 11, 2025 |
| FY2024 | Jul 31, 2023 | ($617.95M) | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | ($283.98M) | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | ($66.10M) | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | $162.96M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $190.05M | Sep 28, 2020 |
| FY2019 | Aug 1, 2018 | $169.32M | Oct 1, 2019 |
| FY2019 | Jul 31, 2018 | $124.98M | Oct 1, 2019 |
| FY2018 | Jul 31, 2017 | $65.90M | Jun 3, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $697.90M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | $547.99M | Sep 11, 2025 |
| FY2024 | Jul 31, 2023 | $401.81M | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | $606.30M | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | $384.91M | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | $366.97M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $254.10M | Sep 28, 2020 |
| FY2019 | Jul 31, 2018 | $437.14M | Oct 1, 2019 |
| FY2019 | Jul 31, 2017 | $263.18M | Oct 1, 2019 |
| FY2019 | Jul 31, 2016 | $223.58M | Oct 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jul 31, 2024 | $398.90M | Sep 16, 2024 |
| FY2024 | Jul 31, 2023 | $397.17M | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | $358.22M | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | $343.83M | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | $330.21M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $317.32M | Sep 28, 2020 |
| FY2019 | Jul 31, 2018 | $305.13M | Oct 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | 0 | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | (1) | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | (2) | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | 0 | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | 0 | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | 0 | Sep 24, 2021 |
| FY2018 | Jul 31, 2018 | 0 | Jun 3, 2019 |
| FY2018 | Apr 30, 2018 | 0 | Jun 3, 2019 |
| FY2018 | Jan 31, 2018 | 0 | Jun 3, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | 0 | Sep 11, 2025 |
| FY2025 | Jul 31, 2023 | (1) | Sep 11, 2025 |
| FY2024 | Jul 31, 2022 | (2) | Sep 16, 2024 |
| FY2023 | Jul 31, 2021 | 0 | Sep 18, 2023 |
| FY2022 | Jul 31, 2020 | 0 | Sep 26, 2022 |
| FY2021 | Jul 31, 2019 | 0 | Sep 24, 2021 |
| FY2018 | Jul 31, 2018 | 0 | Jun 3, 2019 |
| FY2018 | Apr 30, 2018 | 0 | Jun 3, 2019 |
| FY2018 | Jan 31, 2018 | 0 | Jun 3, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 84.53M | Sep 11, 2025 |
| FY2025 | Jul 31, 2024 | 83.03M | Sep 11, 2025 |
| FY2024 | Jul 31, 2023 | 81.44M | Sep 16, 2024 |
| FY2023 | Jul 31, 2022 | 84.08M | Sep 18, 2023 |
| FY2022 | Jul 31, 2021 | 83.19M | Sep 26, 2022 |
| FY2021 | Jul 31, 2020 | 83.46M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | 82.14M | Sep 28, 2020 |
| FY2019 | Jul 31, 2018 | 80.61M | Oct 1, 2019 |
| FY2018 | Jul 31, 2017 | 75.01M | Jun 3, 2019 |
| FY2017 | Jul 31, 2016 | 73.04M | Sep 20, 2017 |